Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

New drug for type 2 diabetes, Effect of insulin on bones

In a groundbreaking finding, a new medicine Galvus (vildagliptin) has been created for people with type 2 diabetes that would lower blood glucose levels without the side effects of other medications.

26 Jul 2010

AVEO's initiation of AV-299 Phase 2 trial for lung cancer triggers $750,000 milestone payment to XOMA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced receipt of a $750,000 milestone payment under its collaboration with AVEO Pharmaceuticals, Inc.. The milestone payment resulted from AVEO's recent initiation of a Phase 2 clinical trial to evaluate its AV-299 antibody for the treatment of non-small cell lung cancer. AV-299 is a humanized antibody to hepatocyte growth factor (HGF).

26 Jul 2010

More time spent sitting linked to higher risk of death

Osteocalcin hormone can regulate glucose levels: Research

Researchers led by Columbia University Medical Center have discovered that the skeleton plays an important role in regulating blood sugar and have further illuminated how bone controls this process. The finding, published in Cell, is important because it may lead to more targeted drugs for type 2 diabetes.

23 Jul 2010

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Bristol-Myers Squibb Company today reported results for the second quarter of 2010 which featured data on key marketed and investigational compounds in its oncology, diabetes and cardiovascular franchises, and growth in sales and EPS. The company also confirmed guidance for 2010 and minimum guidance for non-GAAP EPS in 2013.

22 Jul 2010

New understanding on insulin resistance, action of diabetes drugs may lead to safer medication

A new understanding of insulin resistance and the action of diabetes drugs such as Avandia and Actos could pave the way for improved medications that are more selective and safer, say scientists from Dana-Farber Cancer Institute and The Scripps Research Institute.Our findings strongly suggest that good and bad effects of these drugs can be separated by designing second-generation drugs that focus on the newly uncovered mechanism, said Bruce Spiegelman, PhD, of Dana-Farber, senior author on a report appearing in the July 22 issue of Nature.

22 Jul 2010

Genomics researchers study role of protein in metabolic disorders, heart disease

Studying a protein already known to play an important role in type 2 diabetes and cancer, genomics researchers have discovered that it may have an even broader role in disease, particularly in other metabolic disorders and heart disease. In finding unsuspected links to other disease-related genes, the scientists may have identified future targets for drug treatments.

22 Jul 2010

Scientists uncover new mechanism that reduces risk of type 2 diabetes, cardiovascular disease

In a joint study, scientists from The Scripps Research Institute and the Dana-Farber Cancer Institute at Harvard University have uncovered a novel mechanism that dramatically increases insulin sensitivity and reduces the risk of developing type 2 diabetes and cardiovascular disease.

22 Jul 2010

TCF7L2 protein may play important role in heart disease, other metabolic disorders: Researchers

22 Jul 2010

Amylin reports $164.4M total revenue for quarter ended June 30, 2010

Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2010. The Company reported total revenue of $164.4 million for the quarter ended June 30, 2010, which includes net product sales of $162.5 million. Net loss, excluding a restructuring charge of $3.4 million, was $40.8 million, or $0.28 per share.

22 Jul 2010

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

The VA Maryland Health Care System participated in a landmark national study of more than 10,251 high-risk diabetic adults across the nation, testing if three complementary treatment strategies can reduce the high rate of heart disease and stroke associated with type 2 diabetes and if these treatment strategies can also slow the progression of eye disease associated with diabetes, the leading cause of blindness in working-age Americans.

22 Jul 2010

Tethys Bioscience raises $33 million to drive market uptake of PreDx Diabetes Risk Score blood test

Tethys Bioscience, Inc., a privately held company, announced today that the company has recently raised $33 million, comprising $23 million of venture financing and a $10 million working capital loan. Participants in the venture financing included new investors Greenspring Associates, Inc. (formerly Montagu Newhall Associates, Inc.) and Paul Capital Investments, as well as current investors.

21 Jul 2010

Health Canada grants Osiris Priority Review for Prochymal NDS

Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.

21 Jul 2010

California companies are developing new medicines for diabetes: Report

Pharmaceutical research and biotechnology companies based in California are researching and developing 58 new medicines for diabetes, a chronic disease that afflicts 220 million patients worldwide, including 23.6 million Americans, a new report shows.

21 Jul 2010

Study demonstrates direct link between juvenile compensatory growth and reproduction

University of California, Riverside biologists working on guppies - small freshwater fish that have been the subject of long-term studies - report that rapid growth responses to increased food availability after a period of growth restriction early in life have repercussions in adulthood.

21 Jul 2010

FDA accepts MannKind's resubmission of AFREZZA NDA, sets PDUFA action date

MannKind Corporation today announced that it has submitted, and the U.S. Food and Drug Administration has accepted, MannKind's resubmission of its New Drug Application for AFREZZA™ (insulin human [rDNA origin]) and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act action date of December 29, 2010.

21 Jul 2010

Fero Industries provides comments concerning FDA advisory panel recommendation on diabetes drug Avandia

Fero Industries, Inc. is pleased to provide these comments regarding the recent Food and Drug Administration advisory panel recommendation concerning the GlaxoSmithKline PLC diabetes drug Avandia. The FDA advisory panel has recommended that the agency keep diabetes drug Avandia on the U.S. market despite data clearly showing an increased risk of a heart attack and that GSK covered up their own research that first identified the problem.

20 Jul 2010

Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

New drug for type 2 diabetes, Effect of insulin on bones

AVEO's initiation of AV-299 Phase 2 trial for lung cancer triggers $750,000 milestone payment to XOMA

More time spent sitting linked to higher risk of death

Osteocalcin hormone can regulate glucose levels: Research

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

New understanding on insulin resistance, action of diabetes drugs may lead to safer medication

Genomics researchers study role of protein in metabolic disorders, heart disease

Scientists uncover new mechanism that reduces risk of type 2 diabetes, cardiovascular disease

TCF7L2 protein may play important role in heart disease, other metabolic disorders: Researchers

Amylin reports $164.4M total revenue for quarter ended June 30, 2010

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

Tethys Bioscience raises $33 million to drive market uptake of PreDx Diabetes Risk Score blood test

Health Canada grants Osiris Priority Review for Prochymal NDS

California companies are developing new medicines for diabetes: Report

Study demonstrates direct link between juvenile compensatory growth and reproduction

FDA accepts MannKind's resubmission of AFREZZA NDA, sets PDUFA action date

Fero Industries provides comments concerning FDA advisory panel recommendation on diabetes drug Avandia

Jinfiniti Biosciences moves from clinical studies to developing biomarkers

Novo Nordisk completes patient enrollment in A1chieve study for type 2 diabetes management

Novo Nordisk recruits 60,000th patient in world's largest observational study in insulin therapy

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in